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Abstract The CCN family of genes currently comprises
six secreted proteins (designated CCN1–6 after Cyr61/
CCN1; ctgf/CCN2; Nov/CCN3; WISP1/CCN4; WISP2/
CCN5, WISP3/CCN6) with a similar mosaic primary
structure. It is now well accepted that CCN proteins are
not growth factors but matricellular proteins that modify
signaling of other molecules, in particular those associated
with the extracellular matrix. CCN proteins are involved in
mitosis, adhesion, apoptosis, extracellular matrix produc-
tion, growth arrest and migration of multiple cell types.
Since their first identification as matricellular factors, the
CCN proteins now figure prominently in a variety of major
diseases and are now considered valid candidates for
therapeutic targeting. Dissection of the molecular mecha-
nisms governing the biological properties of these proteins
is being actively pursued by an expanding network of
scientists around the globe who will meet this year at the 5th
International Workshop on the CCN family of Genes,
organized by the International CCN Society (http://ccnsociety.
com), home for an international cadre of collaborators
working in the CCN field.
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Introduction
There is a growing recognition of the importance of cell–
matrix interactions in normal biological processes and in
the pathogenesis of disease. The CCN family and their
cognate proteins are gaining increasing attention for a wide
spectrum of biological events that underlie development
and physiological functions of all organs in the body.
Strikingly, differential and inter-connected expression of the
CCN family members may determine the ultimate behavior
of normal, diseased and cancerous cell types (Table 1 from
Kubota and Takigawa 2007).
The International CCN Society (ICCNS) was founded in
France to stimulate collaborations and provide a home for
the international cadre of researchers working in the CCN
field. A biennial International Workshop on the CCN
family of Genes has been organized since 2000 and its
success has sparked greater interest and recruitment of new
investigators into the field.
On the occasion of the 5th International Workshop that
will be held in Toronto this year (see http://ccnsociety.com),
we present in this short review an updated Perspective on
CCN Biology and Therapeutic Potential.
CCN family of genes and proteins
Nomenclature of the CCN family of genes is based on
cysteine-rich protein 61 (Cyr61; CCN1), connective tissue
growth factor (CTGF;CCN2) and nephroblastoma overex-
pressed protein (Nov; CCN3). The CCN family currently
comprises six secreted proteins with a similar modular
secondary structure (Fig. 1 from Perbal and Perbal 2007;
Fig. 2 and 3 from Leask and Abraham 2006; Fig. 4 from
Kubota and Takigawa 2007). CCN proteins comprise four
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domains: an insulin-like growth factor binding protein
(IGFBP) domain (domain I), a Von Willebrand factor
domain (domain II), a thrombospondin-homology domain
(domain III), and a cysteine knot, heparin-binding domain
(domain IV). An N-terminal located signal sequence and a
hinge region between domains II and III govern secretion
and susceptibility to proteinase cleavage, respectively.
Cleaved fragments may possess unique biological func-
tions, yet to be determined.
Since their first discovery 15 years ago much has been
learned about the biochemistry of CCN proteins and their
expression during development, in normal adult tissues and
in disease. In vitro studies and more recently CCN
transgenic and knockout mice have yielded further insights
and a better understanding of the diversity and complexity
of CCN activities. It is now well accepted that CCN
proteins are not growth factors but matricellular proteins
that modify signaling of other molecules, in particular those
associated with the extracellular matrix. CCN proteins are
involved in mitosis, adhesion, apoptosis, extracellular
matrix production, growth arrest and migration of multiple
cell types. In fact they are expressed early in development
and then are differentially recruited by cells to facilitate
multiple tissue/organ functions, and critically during wound
healing and disease. The field is comprehensively covered
in a recent monograph by Perbal and Takigawa (2005).
The current state of knowledge on the CCN proteins and
interacting protein partners suggest that the CCN proteins
integrate communication between the extracellular matrix
and the cell surface (Fig 1; Perbal and Perbal 2007). As
depicted in Fig. 2 from Leask & Abrahams review (2006)
Fig. 1 Schematic representation of the multiple types of interactions in
which CCN proteins may be involved for signaling cell functions. CCN
CCN proteins, L ligands of receptors, R receptor. ECM extracellular
matrix, P potential partners in the extracellular matrix. From Perbal and
Perbal, JCCS 1:1, 2007 (reproduced with permission)
Fig. 2 Signaling by CCN family members, CCN1, CCN2 and CCN3
bind TGFβ, fibronectin, integrins, LRP1 and HSPGs as indicated.
CCN proteins appear to signal principally through the C-terminal
quarter (domain IV) to activate adhesive signaling pathways and
hence amplify responses to TGFβ or fibronectin. From Leask and
Abraham, J Cell Science 109: 4803–10, 2006 (reproduced with
permission)
Table 1 Angiogenic properties of the CCN family members and their molecular counterparts




Migration Proliferation Adhesion Survival
CCN1 +(Ea)(SMb) (E)(SM) (E)(SM) (E)(SM) + αvβ3, α6β1 aΠbb3, αvβ5, αMβ2 +&−
CCN2 +(E) +(E) +(E) +(E) + αvβ3, α6β1 aΠbb3, αvβ5, αMβ2, α5β1, LRP1,
fibronectin, TrK A, perlecan, BMP-4,
TGF-β< VEGF
+&−
CCN3 +(E) N.D. +(E) +(E) + αvβ3, α6β1, αvβ5, α5β1, Cx43, Notch +&−
CCN4 N.D.c N.D. N.D. N.D. N.D. biglycan, decorin +&−
CCN5 N.D. −(SM) N.D. N.D. N.D. (unknown) +&−
CCN6 N.D. N.D. N.D. N.D. N.D. (unknown) +&−
a Vascular endothelial cells
b Vascular smooth muscle cells
c Not determined
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domains III and IV bind integrins, LRP1 receptor and
HSPG to effect intracellular signaling of key pathways.
CCN proteins mitigate activities of the ECM and associated
growth factors like TGFβ, BMP4, IGFs, and VEGF. This
positions the CCN proteins in the matricellular sphere and
as controllers of cell–matrix communications.
Interestingly, truncated forms of the CCN proteins appear
to translocate to the nucleus where they are postulated to be
involved in transcriptional regulation. Theoretically, this may
serve as the means to transmit environmental information to
central control. In support of this notion that CCN genes are
sensitive to environmental conditions, Fig. 3 from Leask and
Abrahams review (2006) shows how CCN2 can be regulated
by hypoxia and injury/inflammatory mediators.
Figures 5 and 6 from Kubota and Takigawa review (2007)
depicts how CCN proteins figure prominently in angiogenesis
during normal development of tissues and organs and during
tumor angiogenesis. CCN2 is a well established promoter and
inducer of the chondrogenic and osteogenic lineages placing
it in the centre of skeletal formation and deformation.
Looking at the structural similarities amongst the CCN
proteins it was at first not easily understandable what
functional differences could exist. It now turns out that the
CCN proteins likely comprise a homeostatic regulatory
system where one member drives a process while a closely
related member can inhibit the same process. Although the
molecular details of this regulation are not yet well
understood the concept has stirred great interest given that
it may open up new means for therapeutic manipulation of
disease processes. Thus in this battle between the CCN
family members the relative expression levels of individual
CCN proteins, full length and shorter versions, (often
multiple in one site) may ultimately decide the character
of physiological and pathological processes. Figure 7 from
Chaqour and Goppelt-Struebe review (2006) illustrates
another key component in the biology of CCN proteins,
that is, modulation by dynamic forces that act upon cells. In
pathological conditions like hypertension, obstruction and
hemodynamic overload, altered signaling induced by
stretching and compression forces on cells modulates
CCN expression and can lead to either positive compensa-
tory responses or to aberrant outcomes such as fibrosis.
Thus CCN2 has attracted considerable attention as a
fibrosis inducing CCN protein when overexpressed or
when prolonged in its activity. Recent studies have
demonstrated how downregulating CCN2 expression and
function ameliorates the pathological process. Importantly,
Fig. 3 Regualation of the CCN2 promoter and 3′ untranslated region
(3′ UTR). The CCN2 promoter contains recognition sequences for
HIF, Smad, BCE-1, Ets-1, Sp1, as indicated. The 3′ UTR of the gene
(white rectangle) contains a cis-acting element of structure-anchored
repression (CAESAR). Hyoxia, TGFβ and endothelin-1 induce CCN2
as indicated. From Leask and Abraham, J Cell Science 109: 4803–10,
2006 (reproduced with permission)
Fig. 4 A The primary structure of the CCN family proteins and their
reported variants. The general structure is composed of four conserved
modules is illustrated as a nascent translation product with a signal
peptide for secretion (S) at the top. The module names abbreviated
here are fully describe in the text. The modules are then further
abbreviated into a single letter when describing the structure of each
member or its variant. Namely, “I”, “V”, “T” and “C” represent
IGFBP, VWC, TSP1 and CT modules, respectively. In addition to the
names under the unified nomenclature, a few classical and well-
known names are also presented. As briefly noted in the figure, CCN2
variant proteins were reported by Brigstock et al. [52] Kubota et al.
[53], Hinton et al. [54] and Boes et al. [55]. The N-terminal truncated
form of CCN3 was identified in nephroblastomas by Joliot et al. [11].
In the case of CCN4 and CCN6, variants were confirmed at mRNA
level, which were generated through the alternative mRNA splicing
[40–42]. B Multiple molecular interactions by the CCN proteins as
exemplified by CCN2. In this panel also, each module is indicated by
a single letter abbreviation, as explained above. The abbreviation
HSPG stands for heparan sulfate proteoglycans. All of the other
abbreviations are explained in the text. From Kubota and Takigawa,
Angiogenesis 10:1–11, 2007 (produced with permission)
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due to their secretory status, CCN proteins are also
biomarkers of the pathological process.
Experimental resources in the CCN field
In order to dissect and delineate the biological functions of
CCN proteins both in health and disease it is crucial that
there are appropriate and informative experimental models
and reagents. Similar to other fields, the CCN field has
started to more effectively develop its experimental tools.
Transgenic mouse models, in vitro cell line models, and
generation of domain and isoform specific antibodies
constitute a rich source of tools for the studies. Knockout
mouse models of CCN have uncovered a broader role for
CCN proteins in normal and pathological processes [Kawaki
et al. 2008; Heath et al. 2008; Canalis 2007; Kuiper et al.
2007; Kutz et al. 2005; Ivkovic et al. 2003; Brigstock 2002].
Cell line models, especially those capable of transitioning
developmental states, like stem cells, are proving effective in
exploring phenotype/function relationships [Katsuki et al.
2008; Schutze et al. 2007; Djoua et al. 2007; Si et al. 2006].
More recently, domain specific antibodies for CCN3 have
revealed some interesting and somewhat unexpected aspects
of CCN variant localization and potential functions [Lazar et
al. 2007, Subramaniam et al. 2008]. The recognized CCN
protein fragments generated by still uncharacterized pro-
Fig. 6 Assignment of the functioning stages for angiogenic CCN
proteins in the angiogenic events throughout the life. According to the
accumulating findings, CCN1 appears to play a critical role in the earlier
stages of embryonic vascular development, while its function at later
stages, such as tissue regeneration, may not be ruled out. In contrast,
CCN2 is required for the angiogenic events at later stages of development
and it is obviously involved in the regeneration of various tissues.
Although no strict requirement of CCN3 in particular angiogenic events
has yet been specified, it is plausible that CCN3 supports the CCN1 and
CCN2 function in a certain aspects of angiogenic events during the
development and maintenance of the life. The angiogenic roles of CCN4,
5 and 6 still remain to be investigated further, since an association of these
proteins with malignancies has bee suggested. From Kubota and
Takigawa, Angiogenesis 10:1–11, 2007 (produced with permission)
Fig. 5 A The general mechanism of angiogenic action of the CCN
proteins. Through the interaction with integrins, angiogenic CCN
proteins, such as CCN1, CCN2 and CCN3, promote the migration,
adhesion and survival of vascular endothelial cells. CCN proteins are also
known to bind to several ECM components including proteoglycans and
adhesion proteins which furnishes microenvironmental basement for the
neovas-cularization bymodulating the ECM architecture. The function of
other growth factors is occasionally modulated by the direct interaction
with these CCN proteins. B The hypothetical roles of CCN proteins in
the regulation of the development of embryonic cardiovascular systems
at early stages. Based on the findings obtained in vitro, the possible
interactions of CCN proteins with the signaling molecules involved are
illustrated. All of the full designations of the abbreviated names can be
found in the text. Eph is the receptor of ephrin. From Kubota and
Takigawa, Angiogenesis 10:1–11, 2007 (produced with permission)
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teases add further complexity, as does the revelation of a
growing number of different interacting protein partners and
modifiers [see reviews]. There is always the risk that it may
become more difficult to discriminate the trees from the
forest. Nevertheless, having the means to accurately mark the
‘trees’ will hopefully mitigate against this problem. The
ICCNS workshops in concert with JCCS will thus provide
the means and opportunities to address all such issues and
explore the depth of the CCN field within a highly
interactive and open forum.
CCN family as potential therapeutic targets
Given the putative roles that CCN proteins play in multiple
biological processes it is not surprising that aberrant
expression could have pathogenic consequences. In this
context the potential clinical applications for CCN are now
surfacing. A discussion on the applications for CCN3 has
been reported (Perbal 2003) and those for CCN2 have
stemmed from its involvement in a number of vital
functions. Angiogenesis has become a key target for
chemotherapeutic intervention in the process of cancer.
Evidence suggests that this VEGF driven mechanism
focuses on deregulated CCN2.
Overexpression of CCN proteins in adult tissues is a
pathological event so targeting CCN proteins and normalizing
levels would be beneficial and introduce few adverse effects.
Althoughmost of the attention in the field has concentrated on
CCN2, being prominent in angiogenesis, atherosclerosis,
cardiac fibrosis, diabetic nephropathy, systemic sclerosis,
and potentially asthma (the major disease processes in the
western hemisphere and now a growing concern in the eastern
hemisphere) other CCN proteins are now starting to gain
attention as their roles become defined and, as indicated
above, their relationship as a family of homeostasis modu-
lators. Thus for millions of patients, CCN research may one
day reap new therapies for these global burdens.
Current clinical trial perspectives in the CCN field
The major focus of the biopharmaceutical industry has
been thus far on CCN2 because this CCN protein has
been studied in greatest detail and due to its strong
clinical association with fibrosis. A small number of
clinical trials have been conducted using monoclonal
antibodies to CCN2, eg, FibroGen’s FG-3019 in idiopath-
ic pulmonary fibrosis, incipient diabetic nephropathy and
other syndromes; for example, CCN2 levels can be
measured in urine after treatment of hypertensive type
1diabetic nephropathy patients with Losartan. Other
diseases seen as targets for CCN2 are degenerative disc
and cancers such as pancreatic (positively correlated) and
lung cancer where CCN2 may actually interfere with
metastasis. Interim reports on these efforts suggest good
progress. Much more has to be learned about other CCN
proteins from all disease perspectives before therapeutic
targeting is considered.
The strong commitment of several private companies to
development of effective molecular therapeutics for
cancer, inflammation, metabolic and neurological prob-
lems, also falls within the scope of the CCN field where
CCN proteins have been identified as key players in
similar processes. In one example, CCN 1 and CCN3 are
involved in growth promotion or inhibition of a variety of
cancers (including solid and hematopoietic related tumors)
and can serve as prognostic indicators in some cancers.
Evidence suggests that CCN proteins function through
cell membrane receptors, partially identified, including
integrins and can also modulate activities of the IGF
family of growth factors. Thus targeting of CCN proteins
with antibodies or peptides are viable possibilities. In a
second example, CCN2 figures prominently in chondro-
genesis and osteogenesis, relating to musculoskeletal
issues, and importantly in fibrosis, the consequence of
tissue injury and inflammation. As indicated, CCN2 is
already a therapeutic target under active investigation.
Since much more has yet to be explored on how CCN
proteins modulate homeostatic functions there are multi-
ple CCN avenues to be opened that will yield new
mechanistic insights and thereby possibilities for devel-
opment of novel therapeutics.
Fig. 7 Schematic model of the mechanical regulation of Cyr61 and
CTGF indicating different regulatory levels and open questions (see
Conclusion). Mediators, which have been related to mechanical
stimulation of Cr61 or CTGF gene induction, are shown in the middle
panel; details are outlined in the text. From Chaqour and Goppelt-
Struebe FEBS J 273:3639, 2006 (reproduced with permission)
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Conclusion
The emerging CCN field has now uncovered a unique
biological niche in the way cells interact with each other,
with the external matrix and the factors that modulate
critical biological processes of organ development, func-
tional homeostasis, and disease. There is no longer doubt
that the CCN proteins participate fully in governing skeletal
development, the vascular supply, and the architecture of
organs. Manipulating CCN expression changes how bio-
logical systems operate. Abnormal or deregulated expres-
sion of CCN proteins contributes significantly to the
biology of cancer, fibrosis, and inflammatory sequelae.
CCN proteins are therefore seen as obvious targets for
therapeutic intervention. The 5th International Workshop on
the CCN family of Genes will serve again as the main
venue for bringing together the investigators and facilitators
for future development of clinically effective therapeutics
based on the essential biological properties of the CCN
proteins.
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